Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984249 | 0.79 | TDP1 (0.33) | — | |
| SCHEMBL9467787 | 0.76 | REN (0.42) | RENHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL14569206 | 0.67 | ALDH1A1 (0.40) | — | |
| Diethanolamine SCHEMBL1696414 | 0.67 | REN (0.36) | RENHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL17841809 | 0.67 | — | — | |
| SCHEMBL262188 | 0.66 | — | — | |
| SCHEMBL8928181 | 0.65 | REN (0.41) | REN | |
| SCHEMBL4195866 | 0.65 | ALDH1A1 (0.32) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5809103 | 0.65 | REN (0.38) | REN | |
| SCHEMBL10652719 | 0.65 | CA12 (0.43) | RENHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2020-12-29 | — | — | US | claimed |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | UNIVERSITY OF CAPE TOWN (ZA) | 2017-10-19 | — | — | US | claimed |
| EP-3197504-A2 | RADIOPHARMACEUTICAL CONJUGATE OF A METABOLITE AND AN EPR AGENT, FOR TARGETING TUMOUR CELLS | The South African Nuclear Energy Corporation Limited (ZA) | 2017-08-02 | — | — | EP | claimed |
| WO-2016046793-A2 | RADIOPHARMACEUTICAL CONJUGATE | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2016-03-31 | — | — | WO | claimed |
| EP-4556029-A2 | RADIOPHARMACEUTICAL CONJUGATE | The South African Nuclear Energy Corporation Limited (ZA) | 2025-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | EPRS1, FOLH1, SLC46A1 | REN 2276/4885ESR1 118/4885HDAC3 2980/4885 |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | FOLH1, EPRS1, FOLR1 | REN 2873/4885ESR1 230/4885HDAC3 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.